Personalized Medicine: What Are the Up and Coming Therapeutic Areas in Non-Oncology | Diaceutics

Personalized Medicine: What Are the Up and Coming Therapeutic Areas in Non-Oncology

July 7th, 2016

Peter Keeling
Mark Reis
Steve Vitale


For the most part, personalized medicine and targeted therapies have been focused on oncology. However, there is new and exciting activity outside of oncology where biomarker and targeted approaches are proving successful.  This webinar provides insights on those non-oncology therapeutic areas to watch and the data available to support your your targeted therapy launch.

Listen to the webinar to learn:

  • The latest findings in non-oncology targeted therapies
  • How to prepare for targeted therapy launches
  • Competitive intelligence and market research data available for targeted therapy launches

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications
Facebook
Twitter
YouTube
LinkedIn